loading...| Preferred Name | sipuleucel-T | |
| Synonyms |
APC 8015 Provenge |
|
| Definitions |
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1985" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1985" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000038038 |
|
| altLabel |
APC 8015 Provenge |
|
| Component of | ||
| cui |
C0879584 C1706668 C1135133 |
|
| Date last modified |
2007-02-05 |
|
| definition |
A cell-based vaccine composed of autologous antigen-presenting peripheral blood mononuclear cells (enriched for a dendritic cell fraction) that have been exposed to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to prostatic-acid phosphatase (PAP), a protein expressed by prostate cancer cells. Upon administration, the vaccine may stimulate an antitumor T-cell response against tumor cells expressing PAP. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1985" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1985" NCI Thesaurus) |
|
| Legacy PDQ ID |
10559 |
|
| LT |
TRD |
|
| NCI ID |
C1985 |
|
| notation |
CDR0000038038 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
sipuleucel-T |
|
| tui |
T129 T121 |